Skip to main content
Premium Trial:

Request an Annual Quote

Two Become One

Premium

In a new study in Science, researchers from Columbia University and their collaborators describe a gene fusion that seems to cause about 3 percent of glioblastoma tumors, reports New Scientist's Hannah Krakauer.

The two genes — FGFR and TACC — each perform important functions, but when they fuse, they cause chaotic cell division. "The protein that the fused genes code for latches onto the spindles that pull freshly replicated chromosomes into two new cells during cell division," Krakauer says. "The interference means that instead of an even division, the cells end up with different numbers of chromosomes: a phenomenon known as aneuploidy." The team injected the protein formed by the fusion gene into the brains of healthy mice and saw that 90 percent of them developed glioblastomas.

The researchers then administered a drug to block the new protein and found that this doubled the survival time of affected mice, Krakauer adds. "FGFR-TACC fusions could potentially identify a subset of GBM patients who would benefit from targeted FGFR kinase inhibition," the team writes in its paper.

Cancer Minute's sister blog Daily Scan also covers the Science article here.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.